prostate cancer

The money will be used to fund a study of the company's seminal fluid-based prostate cancer test in patient samples.

Results support the ability of the test to not only identify hormonal therapy non-responders, but to predict their improved survival on chemotherapy.

Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.

Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.

Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.

A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.

The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.

Opko has until July 5 to comment on the proposed non-coverage local coverage determination, the most recent development in the test's twisted Medicare narrative.

The collaboration will use Protagen's SeroTag technology to predict patient response to immunotherapy treatment and to monitor patients for adverse effects.

Service revenues were down 8 percent year over year, product revenues grew 26 percent, and revenues from the transfer of intellectual property inched up less than 1 percent.

Pages